文献速递认知障碍与痴呆

血浆苏氨酸181磷酸化tau蛋白与临床前及前驱期阿尔茨海默病的神经精神症状

Plasma Phosphorylated Tau at Threonine 181 and Neuropsychiatric Symptoms in Preclinical and Prodromal Alzheimer Disease.
PubMed 文献 · Neurology · 2022-11-02

研究纳入571例认知未受损或轻度认知障碍的ADNI参与者,用NPI评估轻度行为损害(MBI)。横断面上MBI与较高血浆p-tau181相关(β=8.1%,95%CI 1.4%-15.2%,p=0.02),纵向MBI与p-tau181升高、记忆和执行功能下降及痴呆风险增加相关(风险为3.92倍)。

要点

  • MBI与横断面血浆p-tau181升高相关(β=8.1%,95%CI 1.4%-15.2%),不符合MBI标准的NPS无此关联。
  • 纵向MBI与p-tau181升高(β=0.014%,95%CI 0.003-0.026)及记忆和执行功能下降相关。
  • MBI者痴呆发生率是无NPS者的3.92倍,NPS-not-MBI与无NPS之间无显著差异。

核心结论

  • MBI与认知下降和痴呆风险升高相关,且可能是新发阿尔茨海默相关蛋白病的sequela。
  • MBI在反映阿尔茨海默相关蛋白病方面优于将行为作为替代标志物的现有方法,具有临床和AD试验富集意义。

研究设计与样本

  • 研究纳入认知未受损和轻度认知障碍的阿尔茨海默病神经影像学倡议(ADNI)参与者,共571例,年龄72.2岁,46.8%为女性,64.8%为MCI。
  • MBI状态由神经精神量表(NPI)根据已发表算法推导,基线及第1年访视NPI总分均>0定义为MBI,仅1次访视>0定义为NPS-not-MBI,两次均=0定义为无NPS。
  • 横断面分析采用线性回归,纵向分析采用多水平线性混合效应模型和Cox比例风险模型。

主要发现

  • 横断面上,MBI与较高血浆p-tau181水平相关(β=8.1%,95%CI 1.4%-15.2%,p=0.02),NPS-not-MBI与无NPS相比无此关联。
  • 纵向上,MBI与较高p-tau181相关(β=0.014%,95%CI 0.003-0.026,p=0.02),并与记忆和执行功能下降相关。
  • 生存分析显示MBI的痴呆发生率是无NPS者的3.92倍,NPS-not-MBI与无NPS之间无显著差异。

关键数值与推荐

  • MBI核心标准要求神经精神症状在晚年新发并持续至少6个月。
  • MBI操作化定义:基线和第1年访视NPI总分均>0。
  • NPS-not-MBI操作化定义:仅1次访视NPI总分>0。
  • 无NPS操作化定义:两次访视NPI总分均=0。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Plasma phosphorylated tau at threonine 181 (p-tau181), a well-validated marker of Alzheimer disease (AD) pathologic change, could be a more efficient way to diagnose AD than invasive or expensive biomarkers requiring CSF or PET. In some individuals, neuropsychiatric symptoms (NPS) are the earliest manifestation of AD, observed in advance of clear cognitive decline. However, the few studies assessing AD biomarkers in association with NPS have often had imprecision in capturing behavioral symptoms that represent sequelae of neurodegenerative disease. Thus, the mild behavioral impairment (MBI) construct was developed, framing NPS in a way to improve the precision of risk estimates for disease. MBI core criteria stipulate that NPS emerge de novo in later life and persist for at least 6 months. Here, cross-sectionally and longitudinally, we investigated associations of MBI with p-tau181, neuropsychological test performance, and incident AD. METHODS: Cognitively unimpaired and mild cognitive impairment (MCI) Alzheimer's Disease Neuroimaging Initiative participants were selected. MBI status was derived from the Neuropsychiatric Inventory (NPI) using a published algorithm. NPI total scores at baseline and year 1 visits were used to operationalize MBI (score >0 at both visits), NPS not meeting the MBI criteria (NPS-not-MBI, score >0 at only 1 visit), and no NPS (score = 0 at both visits). Linear regressions were fitted for cross-sectional analyses; multilevel linear mixed-effects and Cox proportional hazards models were implemented to examine the longitudinal associations of MBI with changes in p-tau181 and cognition and incident dementia. RESULTS: The sample included 571 participants (age 72.2 years, 46.8% female, 64.8% MCI). Cross-sectionally (β = 8.1%, 95% CI 1.4%-15.2%, p = 0.02), MBI was associated with higher plasma p-tau181 levels compared with no NPS; NPS-not-MBI was not. Longitudinally, MBI was associated with higher p-tau181 (β = 0.014%, 95% CI 0.003-0.026, p = 0.02), in addition to a decline in memory and executive function. Survival analyses demonstrated a 3.92-fold greater dementia incidence in MBI, with no significant differences between NPS-not-MBI and no NPS. DISCUSSION: These findings extend the evidence base that MBI is associated with elevated risk of cognitive decline and dementia and a sequela of emerging Alzheimer-related proteinopathies. MBI offers a substantial improvement over current approaches that explore behavior as a proxy marker for Alzheimer-related proteinopathies, with both clinical and AD trial enrichment implications.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Ghahremani M, Wang M, Chen HY, et al. Plasma Phosphorylated Tau at Threonine 181 and Neuropsychiatric Symptoms in Preclinical and Prodromal Alzheimer Disease. Neurology. 2022. PMID: 36323521. doi:10.1212/WNL.0000000000201517

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。